Ching-Shih Chen, PhD
College of Pharmacy
Medicinal Chemistry & Pharmacognosy
Molecular Carcinogenesis and Chemoprevention
Prostatic Neoplasms, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Breast Neoplasms, Disease Models, Animal, Carcinoma, Hepatocellular, Cell Transformation, Neoplastic, Liver Neoplasms
Dr. Chen's research focuses on exploring signaling pathways that govern cancer cell survival as targets for drug discovery and design. He employs a multidisciplinary approach to identify new molecular targets by combining a wide range of expertise encompassing synthetic medicinal chemistry, molecular and cell biology, molecular pharmacology, and animal models in his research team. His laboratory has developed a series of novel small-molecule agents that target different molecular defects related to kinase signaling, epigenetics, and cell metabolism in cancer cells, including phosphoinositide-dependent kinase (PDK)-1/Akt inhibitors, histone deacetylase (HDAC) inhibitors, Bcl-2/Bcl-xL inhibitors, protein kinase C delta activators, AMPK activators, and glucose transporter inhibitors. These novel agents mediate antiproliferative effects through mechanisms distinct from that of conventional chemotherapeutic regimens, which will provide a rational approach for molecular targeted cancer therapy.